[Proteinuria in multiple myeloma: Be careful to iatrogeny]

Bull Cancer. 2020 Apr;107(4):519-520. doi: 10.1016/j.bulcan.2020.01.014. Epub 2020 Mar 13.
[Article in French]
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use
  • Autografts
  • Biopsy
  • Bortezomib / therapeutic use
  • Dexamethasone / therapeutic use
  • Female
  • Glomerulosclerosis, Focal Segmental / etiology
  • Humans
  • Iatrogenic Disease
  • Kidney / pathology
  • Lenalidomide / therapeutic use
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / surgery
  • Oligopeptides / adverse effects*
  • Proteinuria / blood
  • Proteinuria / chemically induced*
  • Thalidomide / therapeutic use
  • Thrombotic Microangiopathies / chemically induced*
  • Withholding Treatment

Substances

  • Antineoplastic Agents
  • Oligopeptides
  • Thalidomide
  • Bortezomib
  • carfilzomib
  • Dexamethasone
  • Lenalidomide